Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

7 notable pulmonary fibrosis research efforts 

By Brian Buntz | February 1, 2021

lungs

Image courtesy of Pixabay

Idiopathic pulmonary fibrosis (IPF) is frequently a debilitating disease associated with significant morbidity and mortality. Although a rare disease, its incidence has increased in recent decades, and it leads to more deaths than some cancers. 

The treatment landscape for the condition changed in 2014 when FDA approved the first drugs indicated for IPF, nintedanib from Boehringer Ingelheim and pirfenidone from Roche (OTCMKTS:RHHBY). 

[Related: The pulmonary fibrosis treatment landscape: An interview with an expert]

Research on pulmonary fibrosis has increased in recent years. 

Here’s a summary of notable IPF research: 

  • Boehringer Ingelheim has an international study investigating a phosphodiesterase 4b (BI 1015550) inhibitor in patients with idiopathic pulmonary fibrosis. Researchers have found that the drug has anti-fibrotic effects in animal models and lung fibrosis cellular models. The compound is currently the subject of Phase 2 trials enrolling patients in 25 countries. Phosphodiesterase-4 inhibitors themselves are not new to drug companies. Schering, for instance, developed a selective phosphodiesterase-4 inhibitor known as Rolipram as a possible antidepressant in the 1990s. The molecule has since become a template for other drug discovery and development efforts. Research on Rolipram also continues to be active. 
  • Bellerophon Therapeutics (NSDQ:BLPH) announced in late 2020 that it had enrolled the first patient in its Phase 3 REBUILD trial investigating a pulsed inhaled nitric oxide therapy known as INOpulse as a possible fibrotic interstitial lung disease treatment. Prior clinical data showed the therapy had benefits for pulmonary fibrosis patients engaged in moderate-to-vigorous physical activity. 
  • Genentech, which belongs to Roche (OTCMKTS:RHHBY), has a Phase 3 STARSCAPE trial underway investigating the use of a recombinant human pentraxin-2 protein (PRM-151) in patients with idiopathic pulmonary fibrosis (IPF). Previous clinical research has correlated low serum levels of the pentraxin-2 protein with disease severity in individuals with idiopathic pulmonary fibrosis. 
  • Bristol Myers Squibb (NYSE:BMY) has two Phase 2 trials underway related to pulmonary fibrosis related to the c-Jun N-terminal kinase inhibitor CC-90001 the lysophosphatidic acid receptor 1 antagonist BMS-986278.
  • Galecto (NSDQ:GLTO) is working on small-molecule fibrosis inhibitors such as GB0139, a galectin-3 inhibitor delivered by dry powder inhalation. The company has launched preclinical testing of inhaled galectin-3, a protein that plays a role in fibrosis in several organs. Evidence suggests that GB0139 inhibits fibrosis by targeting macrophages, fibroblasts and epithelial cells. GB0139 has received Orphan Drug Designation from FDA and the European Medicines Agency. 
  • Veracyte (NSDQ:VCYT) has developed the Envisia Genomic Classifier, a genomic test intended to improve the diagnosis of idiopathic pulmonary fibrosis when used in concert with high-resolution computed tomography. The company’s BRAVE study found that the technology had a specificity rate of 91% with less than 10% false positives. 
  • FibroGen (NSDQ:FGEN) has a Phase 3 study known as ZEPHYRUS that is investigating its novel drug for IPF, pamrevlumab. Pamrevlumab is a fully humanized monoclonal antibody that targets activity of connective tissue growth factor, which is a mediator for tissue remodeling and fibrosis. PRAISE, a previous randomized, double-blind Phase 2b trial, showed significantly reduced forced vital capacity (FVC) decline. Adverse effects from pamrevlumab were similar in placebo and treatment arms of the study.

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: Bellerophon Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galecto, Genentech, Idiopathic pulmonary fibrosis, pulmonary fibrosis, Roche, Roche Group, Veracyte
 

Comments

  1. Jerry Hinkey says

    February 12, 2021 at 2:48 am

    I would be interested in any information trails regarding IPF.

    Log in to Reply
  2. Frank Roland ROLLY says

    March 22, 2021 at 6:02 pm

    I suffered deeply with stage four sarcoidosis which progressed to idiopathic pulmonary fibrosis (IPF). I was hospitalized eighteen times in three years, mostly with flare ups and pneumonia. For me, the chronic widespread pain takes my breath away more than the disease itself. At times the pain is so severe I find it difficult to do anything. My life was gradually coming to an end, until I saw World Herbs Clinic on google during my research for alternative help for IPF.. I knew health is wealth thus I decided to give it a try, thank God I did. I got the Lungs disease formula four working days after placing an order. OMG I started noticing change in my breath after one month of taking the herbs formula, My IPF was completely reversed after THREE months of usage. Now i’m happy and free from this deadly disease. I recommend World Herbs Clinic for Lungs disease patients..

    Log in to Reply

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50